Morgan Stanley keeps USD 5.00 target for Cytek Biosciences stock

Published on 10/17/2026 at 20:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cytek earnings are due November 11, 2026. Cytek Biosciences stock was last at USD 5.25 on October 16, 2026, down 2.96 percent versus the Nasdaq prior close.

Analyst view and reporting date

Morgan Stanley maintained a USD 5.00 target on October 9, 2026.
Cytek Biosciences is scheduled to report earnings on November 11, 2026.
Cytek Biosciences stock was last at USD 5.25 at 4:00 p.m. ET on October 16, 2026, 2.96 percent below the Nasdaq prior close of October 15, 2026.
Cytek Biosciences had a market capitalization of USD 682.4 million as of October 16, 2026.

CTKB, US23285D1090, Illustration mit AI erstellt.

Morgan Stanley maintained a Hold rating and a USD 5.00 price target for Cytek Biosciences on October 9, 2026, according to The Globe and Mail. Cytek Biosciences was last at USD 5.25 at 4:00 p.m. ET on October 16, 2026, down 2.96 percent versus the Nasdaq prior close of October 15, 2026.

Revenue remains ahead of estimates

Cytek reported revenue of USD 48.14 million for the second quarter of 2026, compared with analyst estimates of USD 47.31 million. The company also reported a net loss of USD 12.16 million and diluted earnings per share of minus USD 0.09 for the quarter, according to MarketBeat.

Price sits below the yearly high

The Nasdaq-listed stock stood 15.46 percent below its 52-week high of USD 6.21 and 58.61 percent above its 52-week low of USD 3.31 on October 16, 2026. Trading volume was 1,045,418 shares, 6.72 percent below the average volume of 1,120,784 shares.

Valuation and next reporting date

Cytek Biosciences had a market capitalization of USD 682.4 million and a price-to-earnings ratio of minus 8.43 as of October 16, 2026. The next earnings report is scheduled for November 11, 2026, according to TradingView.

Comparison with peers

Cytek Biosciences: minus 2.96 percent, P/E minus 8.43, market capitalization USD 682.4 million.
Thermo Fisher Scientific (NYSE, USD): minus 0.93 percent, P/E 37.12, market capitalization USD 255.1 billion.
Becton, Dickinson and Company (NYSE, USD): minus 1.04 percent, P/E 57.76, market capitalization USD 52.2 billion.

Stock position and investor focus

The latest numbers frame Cytek as a company with revenue above the second-quarter estimate but continued losses. Morgan Stanley's USD 5.00 target is 4.76 percent below the October 16, 2026 Nasdaq price, keeping the analyst view below the latest market level. The November reporting date will provide the next scheduled test of revenue, profitability and demand.